{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:26:53Z","timestamp":1778376413559,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.clgc.2012.08.002","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T05:19:52Z","timestamp":1348550392000},"page":"225-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib"],"prefix":"10.1016","volume":"10","author":[{"given":"Julia","family":"Clemons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Naam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Breaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2012.08.002_bib1","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2012.08.002_bib2","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2012.08.002_bib3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clgc.2012.08.002_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.08.002_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.08.002_bib6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2012.08.002_bib7","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2012.08.002_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2012.08.002_bib10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMc070327","article-title":"Sunitinib and hypothyroidism","volume":"356","author":"Wolter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.08.002_bib11","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2012.08.002_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2012.08.002_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","article-title":"The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma","volume":"104","author":"Shinohara","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2012.08.002_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossmann","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clgc.2012.08.002_bib16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2012.08.002_bib17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2012.08.002_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?","volume":"23","author":"Sabatier","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib21","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A phase I study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2012.08.002_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","article-title":"Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma","volume":"21","author":"van Doorn","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib23","doi-asserted-by":"crossref","unstructured":"Rini B. Does hypothyroidism predict clinical outcome? in Nat Rev Urol, Published online 2010; doi:10.1038\/nrurol. 2010.191.","DOI":"10.1038\/nrurol.2010.191"},{"key":"10.1016\/j.clgc.2012.08.002_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.radonc.2008.05.007","article-title":"Acute severe hypothyroidism induced by sunitinib","volume":"89","author":"Prat","year":"2008","journal-title":"Radiother Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2012.08.002_bib25","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1007\/s12032-010-9757-z","article-title":"Sunitinib-induced severe hypothyroidism with cardiac compromise","volume":"28","author":"Collinson","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib26","first-page":"335","article-title":"Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib","volume":"9","author":"Block","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/annonc\/mdl112","article-title":"Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine","volume":"17","author":"de Groot","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2012.08.002_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/thy.2007.0104","article-title":"Sunitinib (Sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report","volume":"17","author":"Faris","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2009.0125","article-title":"Shrinkage of thyroid volume in sunitinib-treated patients with renal cell carcinoma: a potential marker of irreversible thyroid dysfunction?","volume":"20","author":"Rogiers","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib31","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.clgc.2012.08.002_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/thy.2009.0414","article-title":"Sunitinib induces hypothyroidism with a markedly reduced vascularity","volume":"20","author":"Makita","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib33","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2012.08.002_bib34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/thy.2007.0336","article-title":"Effect of sunitinib on growth and function of FRTL-5 thyroid cells","volume":"18","author":"Salem","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2012.08.002_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy","volume":"183","author":"Fagin","year":"2004","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clgc.2012.08.002_bib36","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MED.0b013e32833d9710","article-title":"Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology","volume":"17","author":"Hercbergs","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clgc.2012.08.002_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2012.08.002_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2004-1231","article-title":"Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society","volume":"90","author":"Gharib","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2012.08.002_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1620\/tjem.222.39","article-title":"Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume","volume":"222","author":"Sakurai","year":"2010","journal-title":"Tohoku J Exp Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731200167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731200167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:21:55Z","timestamp":1761564115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731200167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S155876731200167X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2012.08.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2012.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}